Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1061 - Pneumocystis jiroveci pneumonia (PCP) in patients receiving weekly chemotherapy for metastatic breast cancer

Date

11 Sep 2017

Session

Poster display session

Presenters

Silvana Wijaya

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

S.T. Wijaya, E. Harrison, M. Moody, C. Wilson, L. Hughes-Davies, C. Caldas, H. Earl, R. Baird

Author affiliations

  • Cambridge Breast Unit, Addenbrooke's Hospital, Cb2 0QQ - Cambridge/GB
More

Resources

Abstract 1061

Background

Pneumocystis jiroveci pneumonia (PCP) is thought to be a rare phenomenon in the solid tumour population, particularly in patients with breast cancer. However, it may be increasing within this population as the type and intensity of chemotherapy used changes. There is currently a lack of consensus on PCP prophylaxis in patients who are immunocompromised due to chemotherapy.

Methods

The EPIC electronic health record system was searched for metastatic breast cancer (MBC) patients treated with a weekly chemotherapy (epirubicin/paclitaxel) regimen from October 2014 – February 2016 at Addenbrooke’s hospital (n = 49). A subset of patients diagnosed with PCP (n = 5) was identified. A retrospective analysis was performed on the charts of all patients.

Results

Patients received a mean of 21 weeks (SD = 15, min=1, max=62) of chemotherapy. An overall of 16% (n = 8) of patients had profound lymphopaenia (absolute lymphocyte count

Conclusions

A high incidence of PCP was observed in MBC patients receiving weekly epirubicin/paclitaxel treatment. Additional investigation is needed to define the population of patients at the greatest risk of PCP infection, and to identify those who might benefit from antibiotic prophylaxis.

Clinical trial identification

Legal entity responsible for the study

Cambridge Cancer Centre

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.